E-ISSN 2149-388X | ISSN 2149-0430
 
2025, Vol: 11, Issue: 2
11 / 2Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Cover Letter
License Agreement
Title Page

Short Communication 


Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction

Kevan English, Christine Uwibambe.


Abstract
Obesity is a well-known risk factor for heart failure with preserved ejection fraction (HFpEF). Through recent clinical trials, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have been shown to decrease mortality and improve symptoms in patients with obesity and HFpEF. Based on the new existing data, we suggest a change in clinical practice for physicians globally. Evidence now supports the initiation of GLP-1/GIP agonists in patients with obesity and HFpEF. This short communication reviews some of the most recent data on GLP-1/GIP agonists that support their clinical indications for patients with obesity and heart failure.

Key words: Heart failure with preserved ejection fraction; Obesity; Glucagon-like peptide-1 receptor agonists; Systemic inflammation; Glucose-dependent insulinotropic polypeptide


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Kevan English
Articles by Christine Uwibambe
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

English K, Uwibambe C. Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction. Ulutas Med J. 2025; 11(2): 22-24. doi:10.5455/umj.20250429034140

Web Style

English K, Uwibambe C. Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction. https://www.ulutasmedicaljournal.com/?mno=254988 [Access: July 03, 2025]. doi:10.5455/umj.20250429034140

AMA (American Medical Association) Style

English K, Uwibambe C. Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction. Ulutas Med J. 2025; 11(2): 22-24. doi:10.5455/umj.20250429034140


Vancouver/ICMJE Style

English K, Uwibambe C. Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction. Ulutas Med J. (2025), [cited July 03, 2025]; 11(2): 22-24. doi:10.5455/umj.20250429034140


Harvard Style

English, K. & Uwibambe, . C. (2025) Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction. Ulutas Med J, 11 (2), 22-24. doi:10.5455/umj.20250429034140


Turabian Style

English, Kevan, and Christine Uwibambe. 2025. Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction. THE ULUTAS MEDICAL JOURNAL, 11 (2), 22-24. doi:10.5455/umj.20250429034140


Chicago Style

English, Kevan, and Christine Uwibambe. "Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction." THE ULUTAS MEDICAL JOURNAL 11 (2025), 22-24. doi:10.5455/umj.20250429034140


MLA (The Modern Language Association) Style

English, Kevan, and Christine Uwibambe. "Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction." THE ULUTAS MEDICAL JOURNAL 11.2 (2025), 22-24. Print. doi:10.5455/umj.20250429034140


APA (American Psychological Association) Style

English, K. & Uwibambe, . C. (2025) Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction. THE ULUTAS MEDICAL JOURNAL, 11 (2), 22-24. doi:10.5455/umj.20250429034140


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About THE ULUTAS MEDICAL JOURNAL

The Ulutas Medical Journal (UMJ) is a 3 monthly (quarterly), open access, double-blind peer-reviewed, an international journal. Writing a research pap ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Journal Owner
HAYRİYE ZEHRA ULUTAŞ
Phone: +90 (532) 165 96 39​
E-mail: zehrakenanoglu@hotmail.com​
Address: Alaattin Mah. 30. Ada sok. D11 Blok
No:4 Gungor Uydukent Sitesi  Antakya/HATAY

Editor-In-Chief
KEMAL TURKER ULUTAS, MD, Assc. Prof.
Phone: + 90 (555) 491 35 59​
E-mail: drkemalturker@gmail.com
Address: Alaattin Mah. 30. Ada sok. D11 Blok
No:4 Gungor Uydukent Sitesi  Antakya/HATAY

Publisher Information
SCOPEMED Publishing Co. - TURKEY​
E-mail: scopemed@scopemed.org
Web: https://www.scopemed.com/

 

We welcome your submissions, suggestions, comments, or questions. To reach us, please use one of the methods provided on this page or Email us at ulutasmedicaljournal@gmail.com​

We will respond within 48 to 72 hours.